💉 These vaccines will target respiratory diseases and allow needle-free nasal administration.
🌍 The collaboration aims to simplify production, lower costs, and enhance vaccine distribution.
🚀 Their first focus is an mRNA vaccine against influenza to improve mucosal immunity, potentially transforming respiratory disease prevention globally.
Introduction:
The article discusses the partnership between Ethris and Lonza aimed at developing innovative spray-dried mRNA vaccine formulations for the prevention of respiratory diseases, with a specific emphasis on enhancing stability and ease of administration.
- Ethris and Lonza’s collaboration focuses on creating mRNA vaccines that are stable at room temperature, addressing key supply chain challenges related to vaccine storage.
- The spray-dried formulation aims to facilitate needle-free nasal administration, which could enhance mucosal immunity and lead to improved vaccine efficacy against respiratory viruses.
- The first target for this collaboration is developing a novel mRNA vaccine candidate against influenza, intended to deliver localized immune responses comparable to those of traditional intramuscular vaccines.
- Lonza will employ its expertise in spray-drying and particle engineering to optimize the delivery of Ethris’ stabilized non-immunogenic mRNA and lipid nanoparticle platforms.
- This innovative approach, while highly complex due to the introduction of lipid nanoparticles, represents a significant advancement in the formulation and delivery of mRNA therapeutics.
Conclusion:
The collaboration between Ethris and Lonza marks a pivotal step toward revolutionizing respiratory disease prevention through mRNA-based vaccines. By addressing storage and delivery challenges, this partnership has the potential to transform vaccine accessibility and effectiveness on a global scale, paving the way for future advancements in mRNA therapeutics.
